One intriguing observation stemming from the abovementioned findings is that all modulation of cytokine signaling—activation of IL-33, or inhibition of NLRP3 inflammasome–IL-1 or IL-10—promotes microglial activation and ameliorates Aβ pathology in AD (Table 1). This evidence concerns the gene IL33 and Alzheimer disease.